Evidence map›Paper›PMID 39890222›Full record

ArticleThe Lancet. Global health2025

Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design.

Radhika Gharpure, Annette K Regan, Francisco Nogareda, Allen C Cheng, Christopher C Blyth, Siobhan St George, Q Sue Huang, Tim Wood, Andrew Anglemyer, Kriengkrai Prasert and 19 more

Abstract read
In one paragraph

Article in The Lancet. Global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Radhika GharpureUS Centers for Disease Control and Prevention, Atlanta, GA, USA.
Annette K ReganPan American Health Organization, Washington, DC, USA; Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA; School of Nursing and Health Professions, University of San Francisco, San Francisco, CA, USA. Electronic address: reganann@paho.org.
Francisco NogaredaPan American Health Organization, Washington, DC, USA.
Allen C ChengMonash Infectious Diseases, Monash Health and School of Clinical Sciences, Monash University, Melbourne, VIC, Australia.
Christopher C BlythSchool of Medicine and Wesfarmers Centre of Vaccines and Infectious Disease, Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia; Department of Infectious Diseases, Perth Children's Hospital, Nedlands, WA, Australia; PathWest Laboratory Medicine WA, Queen Elizabeth II Medical Centre, Perth, WA, Australia.
Siobhan St GeorgeInterim Australian Centre for Disease Control, Canberra, ACT, Australia.
Q Sue HuangInstitute of Environmental Science and Research, Wellington, New Zealand.
Tim WoodInstitute of Environmental Science and Research, Wellington, New Zealand.
Andrew AnglemyerInstitute of Environmental Science and Research, Wellington, New Zealand.
Kriengkrai PrasertNakhon Phanom Hospital, Ministry of Public Health, Nonthaburi, Thailand; Faculty of Public Health, Kasetsart University, Sakon Nakhon, Thailand.
Prabda PraphasiriFaculty of Public Health, Kasetsart University, Sakon Nakhon, Thailand.
William W DavisUS Centers for Disease Control and Prevention, Atlanta, GA, USA; Thailand Ministry of Public Health-US CDC Collaboration, Nonthaburi, Thailand.
Chakrarat PittayawonganonDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
Regina ErcoleUnidad centinela de IRAG, Hospital San Juan de Dios, Buenos Aires, Argentina.
Analia IturraUnidad centinela de IRAG, Hospital Zonal de Trelew "Dr Adolfo Margara", Chubut, Argentina.
Walquiria Aparecida Ferreira de AlmeidaMinistry of Health, Brasilia, Brazil.
Francisco José de Paula JúniorMinistry of Health, Brasilia, Brazil.
Marcela Avendaño ViguerasDepartamento de Inmunizaciones, Ministerio de Salud, Santiago, Chile.
Maria Fernanda Olivares BarrazaDepartamento de Epidemiologia, Ministerio de Salud, Santiago, Chile.
Chavely DomínguezGeneral Directorate of Health Surveillance, Ministry of Public Health and Social Welfare, Asunción, Paraguay.
Elena PenayoGeneral Directorate of Health Surveillance, Ministry of Public Health and Social Welfare, Asunción, Paraguay.
Natalia GoñiDepartment of Public Health Laboratories, Ministry of Health, Montevideo, Uruguay.
Daiana TrittenDepartment of Health Surveillance, Ministry of Health, Montevideo, Uruguay.
Paula CoutoPan American Health Organization, Washington, DC, USA.
Daniel SalasPan American Health Organization, Washington, DC, USA.
Ashley L FowlkesUS Centers for Disease Control and Prevention, Atlanta, GA, USA.
Lindsey M DucaUS Centers for Disease Control and Prevention, Atlanta, GA, USA.
Eduardo Azziz-BaumgartnerUS Centers for Disease Control and Prevention, Atlanta, GA, USA.
Sheena G SullivanFielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA; Monash Infectious Diseases, Monash Health and School of Clinical Sciences, Monash University, Melbourne, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnnual estimates of seasonal influenza vaccine effectiveness can guide global risk communication and vaccination strategies to mitigate influenza-associated illness. We aimed to evaluate vaccine effectiveness in countries using the 2023 southern hemisphere influenza vaccine formulation.

methodsWe evaluated end-of-season influenza vaccine effectiveness across eight countries (Argentina, Australia, Brazil, Chile, New Zealand, Paraguay, Thailand, and Uruguay) that used the 2023 southern hemisphere vaccine formulation, with use of a test-negative design. All patients who attended participating hospitals with severe acute respiratory illness were tested by RT-PCR for influenza. We calculated country-specific, network-specific, and pooled vaccine effectiveness against hospitalisation. For countries with sufficient data, we also calculated vaccine effectiveness against intensive care unit (ICU) admission by comparing the odds of vaccination among test-positive cases to that among test-negative controls. We evaluated vaccine effectiveness for groups prioritised for vaccination (young children aged 1-4 years, people aged 5-64 years with underlying health conditions, and older adults aged ≥65 years).

findingsFrom March 5 to Nov 27, 2023, 31 368 individuals were admitted to hospital with severe acute respiratory infection in the eight included countries. Of these, 12 609 individuals admitted to hospital (6452 [51·2%] female and 6157 [48·8%] male) who met inclusion criteria and had complete data were included in the analysis, including 4388 test-positive cases and 8221 test-negative controls. Pooled vaccine effectiveness against hospitalisation with any influenza virus was 51·9% (95% CI 37·2-66·7), with substantial heterogeneity across countries (I

interpretationAcross eight countries, 2023 southern hemisphere vaccines were effective in reducing hospitalisations from influenza illness. Use of common protocols can facilitate data pooling to provide a comprehensive evaluation of vaccine effectiveness across settings.

fundingUS Centers for Disease Control and Prevention cooperative agreements to the Pan American Health Organization and the Thailand Ministry of Public Health; the Australian Government Department of Health and Aged Care; and the New Zealand Ministry of Health.

Indexed as

Influenza, HumanInfluenza VaccinesVaccine EfficacyAdolescentAdultAgedAustraliaChildChild, PreschoolFemaleHospitalizationHumansInfantMaleMiddle AgedNew ZealandInfluenza Vaccines

Identifiers

PMID39890222
PMCPMC11783037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.